Literature DB >> 20082459

Four unrelated patients with Lubs X-linked mental retardation syndrome and different Xq28 duplications.

Oliver Bartsch1, Konstanze Gebauer, Stanislav Lechno, Hilde van Esch, Guy Froyen, Michael Bonin, Jörg Seidel, Barbara Thamm-Mücke, Denise Horn, Eva Klopocki, Christoph Hertzberg, Ulrich Zechner, Thomas Haaf.   

Abstract

The Lubs X-linked mental retardation syndrome (MRXSL) is caused by small interstitial duplications at distal Xq28 including the MECP2 gene. Here we report on four novel male patients with MRXSL and different Xq28 duplications delineated by microarray-based chromosome analysis. All mothers were healthy carriers of the duplications. Consistent with an earlier report [Bauters et al. (2008); Genome Res 18: 847-858], the distal breakpoints of all four Xq28 duplications were located in regions containing low-copy repeats (LCRs; J, K, and L groups), which may facilitate chromosome breakage and reunion events. The proximal breakpoint regions did not contain known LCRs. Interestingly, we identified apparent recurrent breakage sites in the proximal and distal breakpoint regions. Two of the four patients displayed more complex rearrangements. Patient 2 was endowed with a quadruplicated segment and a small triplication within the duplication, whereas patient 3 displayed two triplicated segments within the duplication, supporting that the Fork Stalling and Template Switching (FoSTeS) model may explain a subset of the structural rearrangements in Xq28. Clinically, muscular hypertonia and contractures of large joints may present a major problem in children with MRXSL. Because injection of botulinum toxin (BT-A; Botox) proved to be extremely helpful for patient 1, we recommend consideration of Botox treatment in other patients with MRXSL and severe joint contractures. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20082459     DOI: 10.1002/ajmg.a.33198

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  12 in total

1.  MECP2 Duplication Syndrome.

Authors:  H Van Esch
Journal:  Mol Syndromol       Date:  2011-07-05

2.  De novo MECP2 duplication in two females with random X-inactivation and moderate mental retardation.

Authors:  Ute Grasshoff; Michael Bonin; Ina Goehring; Arif Ekici; Andreas Dufke; Kirsten Cremer; Nicholas Wagner; Eva Rossier; Anna Jauch; Michael Walter; Claudia Bauer; Peter Bauer; Karl Horber; Stefanie Beck-Woedl; Dagmar Wieczorek
Journal:  Eur J Hum Genet       Date:  2011-02-16       Impact factor: 4.246

3.  Major histocompatibility complex class II deficiency complicated by Mycobacterium avium complex in a boy of mixed ethnicity.

Authors:  Dimana Dimitrova; Peck Y Ong; Maurice R G O'Gorman; Joseph A Church
Journal:  J Clin Immunol       Date:  2014-05-01       Impact factor: 8.317

4.  Intellectual disability and epilepsy due to the K/L-mediated Xq28 duplication: Further evidence of a distinct, dosage-dependent phenotype.

Authors:  David Isum Ward; Bethany A Buckley; Eyby Leon; Jullianne Diaz; Margaret Faust Galegos; Sean Hofherr; Amy Feldman Lewanda
Journal:  Am J Med Genet A       Date:  2018-01-17       Impact factor: 2.802

5.  Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans.

Authors:  Vafa Bayat; Isabelle Thiffault; Manish Jaiswal; Martine Tétreault; Taraka Donti; Florin Sasarman; Geneviève Bernard; Julie Demers-Lamarche; Marie-Josée Dicaire; Jean Mathieu; Michel Vanasse; Jean-Pierre Bouchard; Marie-France Rioux; Charles M Lourenco; Zhihong Li; Claire Haueter; Eric A Shoubridge; Brett H Graham; Bernard Brais; Hugo J Bellen
Journal:  PLoS Biol       Date:  2012-03-20       Impact factor: 8.029

6.  Inverted genomic segments and complex triplication rearrangements are mediated by inverted repeats in the human genome.

Authors:  Claudia M B Carvalho; Melissa B Ramocki; Davut Pehlivan; Luis M Franco; Claudia Gonzaga-Jauregui; Ping Fang; Alanna McCall; Eniko Karman Pivnick; Stacy Hines-Dowell; Laurie H Seaver; Linda Friehling; Sansan Lee; Rosemarie Smith; Daniela Del Gaudio; Marjorie Withers; Pengfei Liu; Sau Wai Cheung; John W Belmont; Huda Y Zoghbi; P J Hastings; James R Lupski
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

7.  Xq28 duplications including MECP2 in five females: Expanding the phenotype to severe mental retardation.

Authors:  E K Bijlsma; A Collins; F T Papa; M I Tejada; P Wheeler; E A J Peeters; A C J Gijsbers; J M van de Kamp; M Kriek; M Losekoot; A J Broekma; J A Crolla; M Pollazzon; M Mucciolo; E Katzaki; V Disciglio; M I Ferreri; A Marozza; M A Mencarelli; C Castagnini; L Dosa; F Ariani; F Mari; R Canitano; G Hayek; M P Botella; B Gener; M Mínguez; A Renieri; C A L Ruivenkamp
Journal:  Eur J Med Genet       Date:  2012-03-29       Impact factor: 2.708

8.  Infectious and immunologic phenotype of MECP2 duplication syndrome.

Authors:  Michael Bauer; Uwe Kölsch; Renate Krüger; Nadine Unterwalder; Karin Hameister; Fabian Marc Kaiser; Aglaia Vignoli; Rainer Rossi; Maria Pilar Botella; Magdalena Budisteanu; Monica Rosello; Carmen Orellana; Maria Isabel Tejada; Sorina Mihaela Papuc; Oliver Patat; Sophie Julia; Renaud Touraine; Thusari Gomes; Kirsten Wenner; Xiu Xu; Alexandra Afenjar; Annick Toutain; Nicole Philip; Aleksandra Jezela-Stanek; Ludwig Gortner; Francisco Martinez; Bernard Echenne; Volker Wahn; Christian Meisel; Dagmar Wieczorek; Salima El-Chehadeh; Hilde Van Esch; Horst von Bernuth
Journal:  J Clin Immunol       Date:  2015-02-27       Impact factor: 8.317

9.  MECP2 duplication phenotype in symptomatic females: report of three further cases.

Authors:  Francesca Novara; Alessandro Simonati; Federico Sicca; Roberta Battini; Simona Fiori; Annarita Contaldo; Lucia Criscuolo; Orsetta Zuffardi; Roberto Ciccone
Journal:  Mol Cytogenet       Date:  2014-01-28       Impact factor: 2.009

10.  MECP2 duplication syndrome in a Chinese family.

Authors:  Qingping Zhang; Ying Zhao; Yanling Yang; Xinhua Bao
Journal:  BMC Med Genet       Date:  2015-12-16       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.